CA2046016CCA 2046016CA2046016ACA2046016CCA 2046016 CCA2046016 CCA 2046016CCA 2046016 CA2046016 CA 2046016CA 2046016 ACA2046016 ACA 2046016ACA 2046016 CCA2046016 CCA 2046016C
Authority
CA
Canada
Prior art keywords
htlv
monoclonal antibody
cells
iii
iiimn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute KaketsukenfiledCriticalChemo Sero Therapeutic Research Institute Kaketsuken
Publication of CA2046016A1publicationCriticalpatent/CA2046016A1/fr
Application grantedgrantedCritical
Publication of CA2046016CpublicationCriticalpatent/CA2046016C/fr
Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody